If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
IPO today
Twelve Seas Investment Company (TWLVU)
Kensington Capital Acquisition (KCAC.U)
African Gold Acquisition (AGAC.U)
Fusion Acquisition II (FSNB.U)
Mcap Acquisition (MACQU)
Silverbox Engaged Merger I (SBEAU)
Ibere Pharmaceuticals (IBERU)
Freedom Acquisition I (FACT.U)
Arya Sciences Acquisition IV (ARYD)
Warrior Technologies Acquisition Company (WARR.U)
Austerlitz Acquisition Corporation II (ASZ.U)
Austerlitz Acquisition Corporation I (AUS.U)
Leo Holdings III Corp. (LIII.U)
Upcoming IPO
Property Solutions Acquisition II (PSAGU)
Nightdragon Acquisition (NDACU)
Roblox Corporation (RBLX)
Afc Gamma, Inc. (AFCG)
Roth Ch Acquisition III (ROCRU)
Oscar Health, Inc. (OSCR)
Innovage Holding Corp (INNV)
Priced IPO
Score Media And Gaming, Inc. (SCR)
Briacell Therapeutics Corp. (BCTX)
Clip Interactive, LLC (AUDD)
Greenbox Pos (GBOX)
Virpax Pharmaceuticals, Inc. (VRPX)
Urban-gro (UGRO)
Neximmune, Inc. (NEXI)
Longeveron (LGVN)
Talis Biomedical Corporation (TLIS)
Decibel Therapeutics, Inc. (DBTX)
Loandepot, Inc. (LDI)
Bumble, Inc. (BMBL)
Apria, Inc. (APR)
Signify Health, Inc.. (SGFY)
Bioventus Inc. (BVS)
Biophytis SA (BPTS)
Vallon Pharmaceuticals (VLON)
Viant Technology Inc. (DSP)
Global Internet of People (SDH)
Baosheng Media Group Holdings (BAOS)
More companies

Vallon Pharmaceuticals (VLON)

Sector - Healthcare

Price chart

Return from IPO

Company News

IPO Profile

About company

They are a biopharmaceutical company primarily focused on the development and commercialization of proprietary biopharmaceutical products. They are developing prescription drugs for central nervous system (CNS) disorders and their current focus is the development of drugs with lower potential for abuse than currently available drugs. Their clinical-stage product currently under development is Abuse-Deterrent Amphetamine Immediate-Release, or ADAIR, a proprietary, abuse-deterrent oral formulation of immediate-release (short-acting) dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder, or ADHD, and narcolepsy. They aim to be the first company to introduce a proprietary abuse-deterrent immediate-release dextroamphetamine drug to the market and leverage their agility, flexibility, and know-how to utilize such a position for the benefit of patients, physicians, and their community. It is estimated that over 5 million Americans abuse prescription ADHD stimulants annually. They intend to develop ADAIR for registration through the Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act, or FDCA, approval pathway, which obviates the need for large Phase 2 and Phase 3 efficacy and safety studies.
Pharmaceutical Preparations
David Baker David Baker
Employees Founded
1 2018


Address: Two Logan Square, 100 N. 18th Street, Suite 300, Philadelphia, PA 19103, US

Telephone: (267) 207-3606

Web page:

IPO information

Expected Date 2/10/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
Share prices ($)

Shares & Volumes

Shares Initial (MM) 1.7
Shares Revised (MM) 2.3
Expected offer amount (MM) $15
Realized offer amount(MM) $18.4

Financial Data (last reporting year)

Market Cap (MM) $55.0
Revenues (MM) $0.1
Net Income (Loss) (MM) $-2.3


What do you think will happen with the VLON share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: ThinkEquity

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
ThinkEquity (a division of Fordham Financial Management)

Sector: Healthcare

Tweets about $VLON

Tweets volume:

RT volume:


Google Trends Stats